Evidence map›Paper›PMID 42238338›Full record

ArticleAsian journal of urology2026

Development and validation of prostate-specific membrane antigen-adjusted Prostate Imaging Reporting and Data System: A new approach to enhancing the accuracy of diagnosing treatment-naïve primary prostate cancer.

Xiaoyuan Li, Jieping Song, Xiaochen Yao, Zhenyu Zhao, Qing Zhang, Rushuai Li, Pengjun Zhang, Wenyu Wu, Hongwei Sun, Shuyue Ai and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Xiaoyuan LiDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Jieping SongDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Xiaochen YaoDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Zhenyu ZhaoDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Qing ZhangDepartment of Urology, Nanjing Drum Tower Hospital, Nanjing University, Nanjing, China.
Rushuai LiDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Pengjun ZhangDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Wenyu WuDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Hongwei SunUnited Imaging Research Institute of Intelligent Imaging, Beijing, China.
Shuyue AiDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Fengjiao YangDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Hongqian GuoDepartment of Urology, Nanjing Drum Tower Hospital, Nanjing University, Nanjing, China.
Kuangyu ShiDepartment of Nuclear Medicine, Bern University Hospital, University of Bern, Bern, Switzerland.
Ali Afshar-OromiehDepartment of Nuclear Medicine, Bern University Hospital, University of Bern, Bern, Switzerland.
Longjiang ZhangDepartment of Radiology, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Guangming LuDepartment of Radiology, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Ali Cahid CivelekDepartment of Radiology, Division of Nuclear Medicine and Molecular Imaging, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Feng WangDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The diagnostic efficacy of hybrid positron emission tomography (PET)/MRI in detecting primary prostate cancer (PCa) is limited due to the lack of a quantitative integrated analysis. A new Prostate Imaging Reporting and Data System (PI-RADS) incorporating prostate-specific membrane antigen (PSMA) PET for PET/MRI has been introduced to improve primary detection of PCa. Methods: One hundred and twenty consecutive patients with high clinical suspicion of PCa were enrolled in this prospective study to assess the diagnostic performance of PSMA-adjusted PI-RADS (PAPI-RADS) using Results: In the training group, PAPI-RADS detected more cases of PCa than PI-RADS. PAPI-RADS had a sensitivity of 99%, specificity of 100%, negative predictive value of 92%, and overall accuracy of 99%. PI-RADS had a sensitivity of 94%, specificity of 75%, negative predictive value of 64%, and overall accuracy of 90%. PAPI-RADS was significantly better than PI-RADS in detecting PCa ( Conclusion: PAPI-RADS is significantly better than PI-RADS in detecting PCa. PAPI-RADS can improve the diagnostic accuracy of PCa detection, especially in patients with a PI-RADS score <3 lesions. PAPI-RADS can improve the accuracy of PCa diagnosis and avoid unnecessary biopsies.

Indexed as

Clinically significant prostate cancerPositron emission tomography/MRIProstate cancerProstate Imaging Reporting and Data SystemProstate-specific membrane antigen

Identifiers

PMID42238338
PMCPMC13227207

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.